Methotrexate in inflammatory eye disease

Ocular Immunology and Inflammation

Volumn 11, Issue 2, 2003, Pages 79-82

  Stawell, Richard J ^a  

^a ROYAL VICTORIAN EYE AND EAR HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; METHOTREXATE;

ALOPECIA; ANOREXIA; BEHCET DISEASE; BONE MARROW SUPPRESSION; CHOROIDITIS; DIARRHEA; DOSE RESPONSE; DRUG MECHANISM; EDITORIAL; EYE DISEASE; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; KERATITIS; LIVER TOXICITY; NAUSEA; RHEUMATOID ARTHRITIS; SARCOIDOSIS; SCLERITIS; SIDE EFFECT; STOMATITIS; SYMPATHETIC OPHTHALMIA; TERATOGENICITY; UVEITIS;

ENDOPHTHALMITIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; METHOTREXATE; UVEITIS;

EID: 0042877144     PISSN: 09273948     EISSN: None     Source Type: Journal    
DOI: 10.1076/ocii.11.2.79.15918     Document Type: Editorial

References (24)

1. Chan ES, Cronstein BN. Molecular action of methotrexate in inflammatory diseases. Arthritis Res. 2002;4:266-273.
2. Segal R, Mozes E, Yaron M, Tartakovsky B. The effects of methotrexate on the production and activity of interleukin-1. Arthritis Rheum. 1989;32:370-377.
3. Constantin A, Loubet-Lescoulie P, Lambert N, Yassine-Diab B, Abbal M, Mazieres B, de Preval C, Cantagrel A. Antiinflammatory and immunoregulatory action of methotrexate in the treatment of rheumatoid arthritis: evidence of increased interleukin-4 and interleukin-10 gene expression demonstrated in vitro by competitive reverse transcriptase-polymerase chain reaction. Arthritis Rheum. 1998;41:48-57.
4. Kremer JM. The mechanism of action of methotrexate in rheumatoid arthritis: The search continues. J Rheumatol. 1994;21:1-5.
5. Farber S, Diamond LK, Mercer RD, et al. Temporary remissions in acute leukaemia in children produced by folic antagonist, 4-aminopteroyl-glutamic acid. N Engl J Med. 1948;238:787-793.
6. Gubner R, August S, Ginsberg V. Therapeutic suppression of tissue reactivity. II. Effect of aminopterin in rheumatoid arthritis and psoriasis. Am J Med Sci. 1951;221:176-182.
7. Weinblatt ME, Coblyn JS, Fox DA, et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med. 1985;312:818-822.
8. Giannini EH, Brewer EJ, Kuzmina N, et al. Methotrexate in resistant juvenile rheumatoid arthritis - results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. N Engl J Med. 1992;326:1043-1049.
9. Andersen PA, West SG, O'Dell JR, Via CS, Claypool RG, Kotzin BL. Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in randomized, double-blind study. Annals of Internal Medicine. 1985;103:489-496.
10. Weinblatt ME, Maier AL, Fraser PA, Coblyn JS. Longterm prospective study of methotrexate in rheumatoid arthritis: Conclusion after 132 months of therapy. J Rheumatol. 1998;25:238-242.
11. Weinblatt ME, Weissman BN, Holdsworth DE, et al. Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis: 84-month update. Arthritis Rheum. 1992;35:129-137.
12. Cronstein BN, Naime D, Ostad E. The antiinflammatory mechanism of methotrexate: Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest. 1993;92:2675-2682.
13. Morgan SL, Baggott JE, Vaughn WH, et al. The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 1990;33:9-18.
14. Wong VG, Hersh EM. Methotrexate in the therapy of cyclitis. Trans Am Acad Ophthalmol Otolaryngol. 1965;69:279-293.
15. Shar SS, Lowder CY, Schmitt MA, et al. Low dose methotrexate therapy for ocular inflammatory disease. Ophthalmol. 1992;99:1419-1423.
16. Samson CM, Waheed N, Baltatzis S, Foster CS. Methotrexate for chronic noninfectious uveitis: Analysis of a case series of 160 patients. Ophthalmol. 2001;108:1134-1139.
17. Bom S, Zamiri P, Lightman S. Use of methotrexate in the management of sight-threatening uveitis. Ocular Immunology & Inflammation. 2001;9:35-40.
18. Messmer EM, Foster CS. Destructive corneal and scleral disease associated with rheumatoid arthritis. Cornea. 1995;14:408-417.
19. Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immusuppressive drugs in patients with ocular inflammatory disorders: Recommendations of an expert panel. Am J Ophthalmol. 2000;130:492-513.
20. Kremer JM, Alarcon GS, Lightfoot RW Jr, et al. Methotrexate for rheumatoid arthritis: Suggested guidelines for monitoring liver toxicity. Arthritis Rheum. 1994;37:316-328.
21. Armaly MF. Effects of corticosteroids on intraocular pressure and fluid dynamics. The effects of dexamethasone in the normal eye. Arch Ophthalmol. 1963;70:482-484.
22. Becker B. Intraocular pressure response to topical corticosteroids. Invest Ophthalmol Vis Sci. 1965;4:198-200.
23. Loewenfeld IE, Thompson HS. Fuchs' heterochromic cyclitis: A critical review of the literature. Surv Ophthalmol. 1973;17:394-457.
24. Liesegang TJ. Clinical features and prognosis in Fuchs' uveitis syndrome. Arch Ophthalmol. 1982;100:1622-1626.